Deans' stroke musings: The effect of Compound Danshen Dripping Pills on the pharmacokinetics of steady-state warfarin in rats

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, October 19, 2012

The effect of Compound Danshen Dripping Pills on the pharmacokinetics of steady-state warfarin in rats

I couldn't help but chuckle at testing rat poison(warfarin) in rats. That and the dripping pills
http://www.cabdirect.org/abstracts/20123330687.html;jsessionid=C17D191D49D839672677E7FA54504ED7

Abstract

Objective: To determine the potential interaction between the Chinese herb medicine, Compound Danshen Dripping Pills (CDDP) and a widely used oral anticoagulant warfarin in steady-state in vivo when administered concomitantly. Method: Each day for 4 days the warfarin control group and the warfarin plus single-dose of CDDP group of rats were treated orally with warfarin (0.2 mg/kg, once per day at 8 a. m.), and the warfarin and CDDP combined treatment group of rats were treated orally with warfarin (0.2 mg/kg, once per day at 8 a. m.) and CDDP (500 mg/kg, once per day at 8 a. m.), the warfarin steady-state was achieved after 4 days of treatment, blood samples were collected each day (at 8 a. m.) for HPLC analysis. Until the 5 day the warfarin control group of rats were still treated orally with warfarin (0.2 mg/kg, once at 8 a. m.), the warfarin plus single-dose of CDDP group of rats were treated orally with warfarin (0.2 mg/kg, once at 8 a. m.) and CDDP (500 mg/kg, once at 8 a. m.), and the warfarin and CDDP combined treatment group of rats were still treated orally with warfarin (0.2 mg/kg, once at 8 a. m.) and CDDP (500 mg/kg, once at 8 a. m.), and blood samples were collected at 0, 0.5, 1, 2, 4, 8, 12, 24, 36, 48 h after warfarin-treatment. The concentration of warfarin in blood plasma was determined by high performance liquid chromatography (HPLC). Result: The linear calibration curve ranged from 0.05 to 10 µg/ml, the limit of quantitation (LLOQ) for warfarin was 0.05 ng/ml (r>0.999), moreover, all the validation data including accuracy, precision (intra- and inter-day), sensitivity, recovery, stability, were within the required limits. CDDP did not alter the pharmacokinetic (PK) behavior of warfarin in steady-state in vivo in rats after simultaneous and concomitant treatment. Conclusion: The simultaneous and concomitant treatment of rats with CDDP did not give rise to significant effects on the pharmacokinetics in steady-state of warfarin.